論文 - 詳細
| RRC ID | 31930 |
|---|---|
| 著者 | Mikami Y, Yokoyama K, Tabeta H, Nakagaki K, Arai T. |
| タイトル | Saframycin S, a new saframycin group antibiotic. |
| ジャーナル | J Pharmacobiodyn |
| Abstract |
Saframycin S, structurally the decyano-saframycin A and biosynthetically the precursor of saframycin A, is a new antibiotic and is assumed to be the active principle for the formation of the antibiotic-DNA complex to manifest its activity. In the present study on the biological activity of saframycin S, the antibiotic showed a marked activity against Ehrlich ascites tumor with the doses of 0.5 to 0.75 mg/kg/day for 10 days, and the rate of 40-day survivors was 80 to 90%. However, this antibiotic was less effective against P388 leukemia than saframycin A at the doses tested. Saframycin S also showed the highest antimicrobial activity, in particular against gram-positive bacteria, among the saframycin group antibiotics identified to date. the LD50 of saframycin S was 3.2 mg/kg (i.p.) for ddY mice. The biological activity and toxicity of saframycin S in relation to its structure were described. |
| 巻・号 | 4(4) |
| ページ | 282-6 |
| 公開日 | 1981-4-1 |
| DOI | 10.1248/bpb1978.4.282 |
| PMID | 7264873 |
| MeSH | Animals Anti-Bacterial Agents / pharmacology* Antibiotics, Antineoplastic* Bacteria / drug effects* Isoquinolines / pharmacology Isoquinolines / toxicity Leukemia L1210 / drug therapy Leukemia P388 / drug therapy Male Mice |
| 引用数 | 36 |
| WOS 分野 | PHARMACOLOGY & PHARMACY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 2 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| 病原微生物 | IFM 40009 |